FDA Refreshes Generic Drug Q&A Covering Nitrosamines, Bioequivalence, and Inspection Outcomes

For QA directors and regulatory affairs leads managing generic portfolios, the FDA's updated Generic Drugs Q&A consolidates agency expectations across nitrosamine impurity controls, bioequivalence standards, post-market surveillance, and inspection response, a practical compliance reference at a time when generic oversight scrutiny remains elevated.

The guidance confirms that every approved generic must demonstrate therapeutic equivalence to its reference listed drug, meeting identical standards for active ingredient, dosage form, route of administration, and labeling under 21 CFR Part 314. Appearance differences in color or shape are permissible; deviations in performance characteristics are not. For plant heads, the operative point is that batch-level quality standards apply uniformly across domestic and foreign manufacturing sites, with no regulatory distinction between the two.

On nitrosamines, the Q&A reaffirms that the presence of these impurities does not automatically render a product unsafe, but manufacturers carry the obligation to assess, control, and report levels against established acceptable intake limits. That framing aligns with the agency's existing nitrosamine guidance framework and reinforces that risk-based impurity management is a standing GMP expectation, not a one-time remediation exercise.

The inspection outcomes section is directly relevant to CAPA program owners. The document states that when problems are identified during inspections, FDA takes appropriate steps to ensure patient safety, language that maps to a range of enforcement tools including warning letters, import alerts, and consent decrees. Facilities operating under active commitments should read this as a reminder that post-inspection follow-through is monitored against stated corrective timelines.

MedWatch reporting receives explicit treatment: the Q&A confirms that adverse event and quality complaint reports can trigger regulatory action, and that no fixed threshold of reports is required before the agency acts. For post-market surveillance teams, this reinforces the value of signal detection programs that do not wait for volume to accumulate before escalating internally.

The document also addresses drug shortages in the generic space, noting that quality-related manufacturing disruptions are a contributing factor, a supply-chain read that connects directly to ICH Q10 pharmaceutical quality system requirements around continual improvement and supply continuity planning.

As FDA continues to expand its foreign inspection capacity and generic approval volume, the Q&A serves as a baseline alignment document for teams preparing for pre-approval inspections or responding to post-market surveillance findings.

Source: FDA via What's New: Drugs RSS Feed, 8 June 2026.